Delta-Fly Pharma (4598) · RiskRestated
Risk that medical institutions for the next clinical trial of DFP-14323 remain undecided
First written in FY2023. 1 of 2 entries say "Restated". Latest entry: FY2026.
2entries
4years
0from disclosures
How it moved
Same theme, other companies
Uncertainty over Prolonged or Discontinued Drug Development Pipelines and CommercializationA theme 70 companies write about · 86 as a headwind · 0 as a tailwind
The whole theme swung hardest in 2022: 20 of 40 companies on the "Worse" side.
28 other companies' latest entry also says "Restated".
Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 70 companies compared. The sentences above are computed from all 70.Full recordFilings, disclosures and news, newest first
- FY2026RestatedAnnual report
「また、次の臨床試験は医療機関が未確定であり、臨床試験への取り組み方に医療機関または医師個人で違いがあるなど、計画どおりに進まない可能性があります。」
DFP-14323の次期臨床試験について、医療機関・医師ごとの取り組み方の違いによる計画未達リスクを引き続き記載している。 - FY2023First statedAnnual report
「Medical institutions for the next clinical trial have not yet been finalized, and differences among institutions and individual physicians in their approach to clinical trials may prevent the trial from progressing as planned.」
DFP-14323の次期臨床試験について、実施医療機関が未確定であり、医療機関・医師ごとの取り組み方の違いにより計画どおり進まない可能性を個別リスクとして初めて記載した。